As FDA puts CAR-T safety under microscope, researchers dig into adverse events record of BCMA therapies
Fierce Pharma
DECEMBER 9, 2023
BCMA-targeted therapies are transforming care for multiple myeloma patients. A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions.
262 
Let's personalize your content